STOCK TITAN
  1. Home
  2. News
  3. CBAY

Cymabay Therapeu (CBAY) Stock News, Oct 2023-Jan 2024

CBAY Nasdaq
News

New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
clinical trial
-
News

CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
conferences
-
News

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
fda approval
-
News

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
none
-
News

CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting®

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
clinical trial
News

CymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
earnings
-
News

CymaBay Therapeutics to Present at Upcoming Investment Conferences

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
conferences
-
News

CymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
News

CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
conferences earnings